Hematopoietic SCT (HSCT) has been used as a curative therapy for pediatric malignancies. Survivors of HSCT are at risk for disease recurrence, late morbidity and mortality. We assessed late mortality (X2 years post-HSCT) in a population-based cohort of children who underwent HSCT for a malignancy. Mortality outcomes were determined by linking a clinical transplant database with the Canadian province of Ontario's pediatric cancer mortality files. Seven hundred and fifty-four children underwent HSCT (371 allogeneic, 383 autologous). Of the 479 (63.5%) who were alive X2 years post HSCT, 98 (20.5%) suffered a late death. Late mortality in the allogeneic HSCT group was 14.9% (median follow-up 10.0 years; range: 2.0-25.6 years), mainly due to relapse of the primary malignancy (64.7%). Chronic GVHD and second malignancies were not major causes of late mortality. A total of 25.5% suffered a late death following autologous HSCT (median follow-up 6.7 years; range: 2.0-22.2 years). Recurrence of the primary malignancy accounted for 87.5% of these deaths. Recurrence of the primary malignancy is the predominant cause of late mortality after HSCT. In contrast to studies of adult patients, non-relapse mortality is less common in children, and death due to chronic GVHD and secondary malignancies is uncommon.
INTRODUCTION
Hematopoietic SCT (HSCT) has become a standard component of therapy for several pediatric malignancies. 1 As HSCT improves survival, and supportive care advances diminish the acute toxicities of HSCT, the risk of late complications in survivors is of increasing concern. The high burden of morbidity after HSCT often leads to late mortality, with survivors expected to have as much as a 30% shorter life expectancy than the general population. 2 Late mortality is usually defined as death from any cause occurring 2 or more years after HSCT. 3, 4 Most studies that have evaluated late mortality after HSCT have focused on combined cohorts of adults and children, or on adult populations alone. [2] [3] [4] For example, among 2574 5-year survivors of allogeneic and autologous HSCT in one study, only 23.6% were transplanted during childhood 2 and pediatric outcome data was not presented separately. Late mortality in that cohort was 12%, with recurrent malignancy representing the most common cause of death. 2 In survivors of allogeneic HSCT, relapse of the primary disease and chronic GVHD are the most frequent causes of late mortality in adults. 3, 5 Relapsed disease and second malignancies are the main causes of late mortality after autologous HSCT. 6, 7 However, as the distribution of cancers, for which HSCT is indicated differs between adults and children, 4 the contribution of relapse to late mortality in children may not mirror that seen in adult cohorts. Furthermore, the risk for chronic GVHD is lower in children compared with adults. 8 Consequently, immunosuppressive therapy is used less frequently and immune re-constitution occurs more rapidly in children. 8 This may modify the risk of and risk factors for late mortality. Children and adults also differ in the impact of HSCT on organ function, with children often recovering more rapidly from the impact of intensive chemotherapy. Consequently, it is important to evaluate the risk of late mortality separately in survivors of pediatric HSCT as combined data or extrapolation of adult data might not reflect the true risk or advantage in children.
The present study is focused on a population-based cohort of children treated with HSCT in the Canadian province of Ontario. All five pediatric cancer centers in the province refer children who require HSCT to the Hospital for Sick Children (SickKids) in Toronto. SickKids performs over 99% of pediatric HSCT in Ontario, and 40% of pediatric HSCT in Canada. The availability of this provincial cohort provides a unique opportunity to conduct a population-based analysis of the incidence and risk factors for late mortality after pediatric HSCT.
PATIENTS AND METHODS

Study population
After obtaining permission from the hospital's Research Ethics Board, we compiled information on the cohort of all children (aged 0-19.9 years at HSCT), who underwent a HSCT for a malignant indication at SickKids between 1st January 1985 and 31st December 2008. Demographic, diagnostic and treatment information had been collected prospectively in the hospital's Bone-Marrow Transplant Database. This data set was linked with the provincial pediatric cancer registry, the Pediatric Oncology Group of Ontario Networked Information System (POGONIS), which holds data on mortality (provided by the Registrar General of Ontario) and second malignancies (ascertained from the Ontario Cancer Registry) that occurred in survivors' pediatric and adult years.
Descriptive data was generated to characterize the cohort in terms of age at transplant (0-3, 4-9 and 10 þ years), sex, first primary cancer type (based on International Classification of Childhood Cancer major classification), 9 time period of transplant (1985-1989, 1990-1994, 1995-1999, 2000-2004 and 2005-2008) , transplantation type (autologous vs allogeneic; related vs unrelated donor), conditioning regimen (chemotherapy alone vs TBI containing regimen), graft type (BM, cord blood, matched PBSC, and unmatched PBSC), the number of disease relapses before transplant and the number of disease relapses after transplant. During the study period, our standard immunosuppressive therapy for living donors (used in greater than 95% of cases) was CYA in combination with three to four doses of MTX. For the cord blood transplant recipients, we used a combination of CYA and corticosteroids.
Late mortality was classified as any death that occurred 2 or more years after HSCT. Patients who died while in relapse were considered to have a relapse-related death. Causes of non-relapse mortality (NRM) were abstracted from the patients' charts. The presence of chronic GVHD was recorded for all patients who suffered from NRM.
Statistical analysis
Continuous variables were reported using the mean and s.d. or median and range, and dichotomous variables were reported as the percentage with the condition. OS was calculated as the time from HSCT to the date of death or end of the follow-up period (31st December 2010). Survival curves were estimated using Kaplan-Meier methods. Cox regression models were used to simultaneously assess the risk factors as outlined and their association with late mortality. No covariate selection procedures were employed and all seven factors were identified a priori (age at transplant, sex, year of transplant, transplant type (where applicable), primary diagnosis, relapse pretransplant and conditioning regimen).
All cause standardized mortality ratios (SMRs) were calculated using ageand sex-matched mortality information from the Ontario population. Exact confidence intervals (CI) for the SMRs were calculated following the methods of Liddell.
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RESULTS
Study population
Between January 1985 and December 2008, 764 pediatric patients underwent a HSCT for a malignant indication. Ten of these patients could not be linked to Pediatric Oncology Group of Ontario Networked Information System because of missing or inaccurate identifiers, which resulted in 754 patients available for inclusion in the cohort.
Of these 754 patients, 371 (49.2%) had an allogeneic HSCT and 383 (50.8%) had an autologous HSCT. Of the 754 patients, 479 (63.5%) remained alive 2 years after HSCT (with a median followup of 7.9 years, range: 2.0-25.6 years) and comprised the cohort for the present analysis ( Figure 1 ; Table 1 ). Of the 479 2-year survivors, 98 (20.5%) subsequently died at a median of 3.5 years (range: 2.0-15.5 years) after HSCT. Median follow-up of the 381 patients still alive at last follow-up was 10.4 years (range: 2.0-25.6 years). The SMR for the 479 2-year survivors was 547 (95% CI: 444-666).
Late mortality after allogeneic HSCT Of the 371 pediatric patients who underwent an allogeneic HSCT, 228 (61.5%) were alive 2 years after HSCT ( Table 1 ). The median age of these 228 survivors at the time of transplantation was 8.0 years (range: 0.3-19.0 years). One hundred and forty-seven received a related-donor HSCT and 81 received an unrelated donor HSCT. Overall, 34/228 (14.9%) experienced a late death ( Figure 2 ); 20/147 (13.6%) after a related donor allogeneic HSCT, and 14/81 (17.2%) after an unrelated donor allogeneic HSCT. The SMR for the 228 2-year survivors of allogeneic HSCT was 370 (95% CI: 256-517).
Among patients who were alive at 2 years after their HSCT, 5-year OS (from the time of HSCT) was 88.2% and 10-year OS was 85.1% ( Figure 2 ). Of the 34 patients who suffered late mortality after allogeneic HSCT, 22 (64.7%) died of relapsed disease at a median of 3.3 years (range: 2.1-12.5 years) from transplant. Ten (29.4%) died of NRM at a median of 4.0 years (range: 2.5-15.5 years) from transplant. The cause of death was unknown in two subjects. The causes of late NRM after related donor allogeneic HSCT were infection with respiratory failure (two patients), chronic GVHD (one patient), pulmonary hypertension (one patient) and seizure disorder (one patient). The causes of late NRM after unrelated donor HSCT were infection and respiratory failure (four patients, one of whom also had chronic GVHD) and chronic GVHD alone (one patient). Table 2 presents the multiple-variable model of risk factors for late mortality after allogeneic HSCT. No statistically significant associations were found between age, gender and donor type (related vs unrelated) and the hazard of death. In addition, we did not find a relationship between graft source (BM vs peripheral stem cells vs cord blood stem cells) and late mortality.
Late mortality after autologous HSCT Of the 383 patients who underwent an autologous HSCT, 251 (65.5%) were alive at 2 years after transplantation. Of these, 64 (25.5%) experienced a late death at a median of 6.7 years (range: 2.0-22.2 years) after HSCT. Patient characteristics are presented in Table 1 . Patients with neuroblastoma comprised the majority of the autologous HSCT cohort (n ¼ 98; 39.0%); 39 of these neuroblastoma patients (39.7%) suffered a late death. The SMR for the 251 2-year survivors of autologous HSCT was 733 (95% CI: 565-937).
The 5-year OS from the time of HSCT was 75.6% and the 10-year OS was 71.0% ( Figure 2) . Of the 64 patients who suffered a late death after autologous HSCT, 57 (89.1%) died as a result of relapse of their primary disease. Three patients (4.6%) suffered late NRM, two of hepatic failure and one after developing a second malignancy after treatment for a soft tissue sarcoma. The cause of death was unknown for four patients. Most of the data published on late mortality after pediatric allogeneic HSCT is reported in combination with data on adults; there are no reports of late outcomes in children alone. The largest study of late mortality after HSCT reported on a cohort of 10 632 2-year survivors (children and adults) collected by the International Bone Marrow Transplantation Registry. The cumulative mortality was 15% at 10 years after HSCT. 4 Recurrent disease was Late mortality post SCT T Schechter et al the most common cause of death. Similarly, a study of 6691 patients (adults and children) demonstrated that those who had survived for 2 years after transplant had an 89% probability of living for more than 5 years after HSCT. This cohort included patients transplanted for both malignant and non-malignant indications, explaining the better survival than was observed in the prior reports and in our study. 1 The most common reported cause of NRM after allogeneic HSCT is chronic GVHD, followed by infections, second malignancies, respiratory and cardiovascular complications. 2, 11 Studies that include mainly adults have demonstrated a much higher incidence of late NRM than observed in our study. 1, 12 These studies did not report the causes and risk for NRM in patients who underwent HSCT during childhood separately. Conflicting results regarding the effect of age at transplant on mortality have been published. Socie et al.
1 demonstrated lower mortality in patients younger than 15 years at HSCT, while Martin et al.
2 did not identify a relationship between age at transplant and late mortality. NRM accounted for only 4.3% of late mortality in our allogeneic HSCT recipients, with infection representing the most common cause of NRM. The Bone Marrow Transplantation Registry has reported that fatal infections are a prevalent cause of late mortality, with risk factors for infectious death including acute GVHD, chronic GVHD, CMV infection, mismatched or unrelated donor and TBI. 5, 13 Chronic GVHD has been identified as the primary isolated risk factor for late infections after HSCT in adult patients. 14 These infections have been attributed to functional asplenia, 14 impaired T and B cell reconstitution and the immunosuppressive therapy used to treat chronic GVHD. 15 Similarly, numerous other studies in adults have demonstrated that chronic GVHD is a significant risk factor and a major cause of late mortality regardless of infectious complications. 1, 3, 16, 17 As chronic GVHD is less prevalent in children, we observed lower rates of death due to chronic GVHD (only 1.2%) and infections (2.2%) compared with the adult literature. 1, 3, 4 However, it has been shown that once chronic GVHD occurs, 5 year OS is only 60%. 18 Second malignant neoplasms have also been demonstrated to be a significant cause of late mortality in adults. 1, 16 Survivors of allogeneic HSCT have been shown to be at a 12-fold increased risk of developing another malignancy when compared with the general population. 12 Although the risk for the development of a second malignant neoplasm increases with increasing time from HSCT, we did not find new malignancies to be a major cause of late mortality despite a median follow-up of 10.0 years. The reason for the difference between adults and children post-HSCT is yet to be explained. As our cohort ages, SMN might become more prevalent.
Data regarding whether TBI increases the risk for late mortality is conflicting, with some reports suggesting an increased risk mainly due to increased late infections, 13 while others show no impact on late mortality. 2, 12 In our analysis, there was no difference in late mortality based on the use of TBI conditioning.
Despite surviving 2 years from transplant, 25.5% of children in our cohort treated with autologous HSCT suffered a late death. Most of these deaths occurred as a result of relapsed disease, with only three (1.2%) patients dying from NRM without evidence of relapse. We were not able to determine the cause of death in four patients; however, even if these deaths are attributed to NRM, only 2.7% died from NRM. Studies in adults have reported a similarly high risk for death due to late relapse, but the risk for NRM is substantially higher in adult cohorts. For example, Bhatia et al. 12 reported that 31.2% of 854 patients (90% of whom were 418 years of age at time of HSCT) died 2 or more years after autologous HSCT for a hematologic malignancy. Although relapse accounted for the majority of deaths, 13.7% of the cohort experienced NRM, a rate 10 times higher than our cohort. Onequarter of these deaths were due to second malignancies. The median follow-up in the cohort followed by Bhatia et al.
12 was 7.6 years, compared with 10.0 years in our study; thus, length of Abbreviation: CI ¼ confidence interval. Note: *P-value o0.05.
Late mortality post SCT T Schechter et al follow-up does not account for the discrepant results. As late organ dysfunction such as cardiovascular disease may not be present in children as early as it might be in adults, a longer follow-up of young children to fully understand the life-time risk for late effect of HSCT is required. Neuroblastoma is a unique indication for autologous HSCT in children. In a Children's Oncology Group study of stage IV neuroblastoma treated with autologous HSCT and 13-cis-retinoic acid, the 5-year risk for mortality was 41%. 6 Similarly, we observed a 40% risk of late mortality in children treated for high-risk neuroblastoma, mainly due to recurrence. Although HSCT has significantly improved outcomes in these patients, relapse is still common. Treatment-related myelodysplastic syndrome and myeloid leukemias have also been reported in 1 to 8% of patients after autologous HSCT high-risk neuroblastoma. 19, 20 This was not a cause of death in any patients in our study.
Although our cohort is smaller than that followed by large registries such as Bone Marrow Transplantation Registry, it is strengthened by its focus on patients who underwent transplant for a malignant disease. In addition, it captures the entire population of children treated with transplant in Canada's largest province, and takes advantage of linkage to the provincial mortality registry to determine cause of death. We have demonstrated that relapse of the primary malignancy is a prevalent cause of mortality, even in pediatric patients who have survived for 42 years after their HSCT. In contrast to studies of adult patients, NRM is low in pediatric patients and chronic GVHD and secondary malignancies are uncommon causes of late NRM. As late mortality continues to occur even 10 or more years after transplant, regular follow-up of HSCT survivors by medical teams familiar with the long-term risks of therapy is warranted.
